Nordic Nanovector, listed on the Oslo Stock Exchange, has entered into an agreement for a business combination between Nordic Nanovector and Thor Medical. CLP is acting as legal advisor in the transaction, together with Carnegie as financial advisor for Nordic Nanovector.
Through the transaction, Nordic Nanovector will receive access to promising new technology that enables the development and production of radionuclides for use in cancer treatment. The transaction is made as a share exchange transaction, with an agreed exchange ratio of 50/50. The transaction is subject to, among other things, approval by the general meeting in Nordic Nanovector, and is expected to be completed during Q2 2023. Following completion of the transaction, Nordic Nanovector will change its name to Thor Medical ASA.
We thank Nordic Nanovector for the vote of confidence and congratulate the parties with the transaction!
Further information about the transaction is available at https://newsweb.oslobors.no/message/592601.